InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,344.16
(
0.47%
)
US TECH 100
18,024.00
(
0.56%
)
Dow Jones
39,497.54
(
0.13%
)
Brent Oil
79.49
(
0.00%
)
Bitcoin
60,672.46
(
-0.34%
)
Post# of 252819
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 120250
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: iwfal post# 68068

Sunday, 05/03/2009 9:45:00 PM

Sunday, May 03, 2009 9:45:00 PM

Post# of 252819
AZN – The JUPITER trial is having a material effect on Crestor sales, evidently. Worldwide 1Q09 sales of Crestor were $969M, +35% year-over-year in local currencies.

Crestor’s TRx share in the US anti-cholesterol market rose to 10.3% in March 2009, and Crestor is the only statin that is gaining US market share.

Source: http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q1-2009/AZN-Q1-results-09-Narrative.pdf


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up